Expression of transporters involved in urine concentration recovers differently after cessation of lithium treatment.
Patients receiving lithium therapy, an effective treatment for bipolar disorder, often present with acquired nephrogenic diabetes insipidus. The nephrotoxic effects of lithium can be detected 3 wk after the start of treatment and many of these symptoms may disappear in a few weeks after lithium use is stopped. Most patients, however, still have a urine-concentrating defect years after ending treatment. This prompted an investigation of the transporters involved in the urine concentration mechanism, UT-A1, UT-A3, aquaporin-2 (AQP2), and NKCC2, after discontinuing lithium therapy. Sprague-Dawley rats fed a Li2CO3-supplemented diet produced large volumes of dilute urine after 14 days. After lithium treatment was discontinued, urine osmolality returned to normal within 14 days but urine volume and urine urea failed to reach basal levels. Western blot and immunohistochemical analyses revealed that both urea transporters UT-A1 and UT-A3 were reduced at 7 and 14 days of lithium treatment and both transporters recovered to basal levels 14 days after discontinuing lithium administration. Similar analyses demonstrated a decrease in AQP2 expression after 7 and 14 days of lithium therapy. AQP2 expression increased over the 7 and 14 days following the cessation of lithium but failed to recover to normal levels. NKCC2 expression was unaltered during the 14-day lithium regimen but did increase 14 days after the treatment was stopped. In summary, the rapid restoration of UT-A1 and UT-A3 as well as the increased expression of NKCC2 are critical components to the reestablishment of urine concentration after lithium treatment.
Blount
Mitsi A
MA
Department of Medicine, Renal Division, Emory University School of Medicine, Atlanta, Georgia, USA. mabloun@emory.edu
Sim
Jae H
JH
Zhou
Rong
R
Martin
Christopher F
CF
Lu
Wei
W
Sands
Jeff M
JM
Klein
Janet D
JD
D000818:Animals; D018692:Antimanic Agents; D051399:Aquaporin 2 / Q000378:metabolism; D015153:Blotting, Western; D018500:Diabetes Insipidus, Nephrogenic / Q000139:chemically induced / Q000378:metabolism* / Q000503:physiopathology / Q000652:urine; D007150:Immunohistochemistry; D007668:Kidney / Q000378:metabolism* / Q000503:physiopathology; D007671:Kidney Concentrating Ability; D016651:Lithium Carbonate; D008297:Male; D026901:Membrane Transport Proteins / Q000378:metabolism*; D009994:Osmolar Concentration; D051381:Rats; D017207:Rats, Sprague-Dawley; D020127:Recovery of Function; D028021:Sodium-Potassium-Chloride Symporters / Q000378:metabolism; D064466:Solute Carrier Family 12, Member 1; D013997:Time Factors; D000096982:Urea Transporters
D018692:Antimanic Agents; D051399:Aquaporin 2; D016651:Lithium Carbonate; D026901:Membrane Transport Proteins; D028021:Sodium-Potassium-Chloride Symporters; D064466:Solute Carrier Family 12, Member 1; D000096982:Urea Transporters; C496025:Aqp2 protein, rat; C578716:Slc12a1 protein, rat